U.S. markets closed
  • S&P Futures

    4,511.75
    +0.50 (+0.01%)
     
  • Dow Futures

    35,336.00
    +13.00 (+0.04%)
     
  • Nasdaq Futures

    15,391.75
    -6.75 (-0.04%)
     
  • Russell 2000 Futures

    2,272.80
    0.00 (0.00%)
     
  • Crude Oil

    83.05
    +0.09 (+0.11%)
     
  • Gold

    1,768.30
    -2.20 (-0.12%)
     
  • Silver

    23.64
    -0.24 (-1.02%)
     
  • EUR/USD

    1.1636
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • Vix

    15.70
    -0.61 (-3.74%)
     
  • GBP/USD

    1.3795
    +0.0001 (+0.01%)
     
  • USD/JPY

    114.6590
    +0.2990 (+0.26%)
     
  • BTC-USD

    64,055.36
    +1,934.12 (+3.11%)
     
  • CMC Crypto 200

    1,483.81
    +20.45 (+1.40%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,403.12
    +187.60 (+0.64%)
     

Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., July 15, 2021--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results, and provide a corporate update.

To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 5749439. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005124/en/

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com